#Sponsored by: @Genentech

Tune in to #FAACTsRoundtable #Podcast: Updates from #ACAAI25

Listen to #FAACT's Ep. 264:
www.buzzsprout.com/848314/episo...

#FoodAllergy #FoodAllergies #Allergy #Asthma #Anaphylaxis #AllergyAwareness #FoodAllergyAwareness #EPIT #OIT #SLIT #Epinephrine #OralFoodChallenges

Pediatric HAE Study Supports Safety and Early Relief With Sebetralstat Sebetralstat provides comparable drug exposure and early symptom relief in children aged 2 to 11 years with HAE as that seen in older patients.

#ACAAI25: #Sebetralstat appears to be a safe, effective, and easy-to-use oral treatment for acute #HAE attacks in children aged 2 to 11 years, with drug exposure and early symptom relief comparable with older patients.

Read more: https://bit.ly/4oyKrOL

#RareDisease #KONFIDENTKID #MedSky

Couldn't attend #ACAAI25? We've got you covered.

Catch up on our coverage ⬇️ #MedSky

We recently presented our outcomes at #ACAAI25! 🌟 Thank you to everyone who stopped by to discuss our insights on aligning #clinician, #patient, and #caregiver education in pediatric #AtopicDermatitis. 🔗 bit.ly/3XnbGjm
 
@aafanational.bsky.social, #DBSA, #NAPNAP, #ACAAI

Our CSO, Dr. Suzanne Kelly, shared insights on allergen levels in NAC vs AEC at #ACAAI25. Don’t miss our second poster today at 12:15 PM at Monitor 20 - allergen sensitization trends in our research patient database.

RMT @ ACAAI 2025 — Red Maple Trials Join us in Orlando as we attend the ACAAI Annual Meeting.

Excited to be at #ACAAI25 in sunny Orlando! 🌴☀️Looking forward to connecting with colleagues, learning about the latest in allergy & immunology, and sharing insights. View our posters here: www.redmapletrials.com/news/acaai-2...

BW-20805 Sustains Prekallikrein Suppression in Phase 1 HAE Trial Mean maximum reductions of prekallikrein from baseline were 75% at 50 mg, 87% at 150 mg, 94% at 300 mg, and 95% at 600 mg.

#ACAAI25: BW-20805 safely and significantly reduced levels of #PlasmaPrekallikrein for up to 24 weeks after a single dose in healthy volunteers, supporting its potential as a long-acting preventive therapy for #HereditaryAngioedema (HAE)

Read here: https://bit.ly/3Jt4YFs

#RareDisease #BW20805 #HAE

Garadacimab Demonstrates Long-Term Safety and Protection in HAE Long-term prophylaxis with garadacimab achieved a 94.9% reduction in HAE attack frequency from baseline.

#ACAAI25: #Garadacimab provided durable efficacy and consistent safety for up to 5.5 years in patients with #HereditaryAngioedema (#HAE), with sustained prevention of attacks and no serious treatment-related adverse events.

Read more: https://bit.ly/3LssjI0

#RareDisease #MedSky #RareSky

One-Time Infusion of Lonvo-Z May Safely Prevent Attacks in HAE Adverse events were common but were mostly mild to moderate reactions that resolved rapidly.

#ACAAI25: A single 50-mg infusion of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (#HAE) appears to offer high rates of attack-free and long-term prophylaxis (#LTP)-free status.

Read here: https://bit.ly/3JCy3yg

#RareDisease #HereditaryAngioedema #LonvoZ #MedSky

Don't miss our outcomes poster presentation tomorrow Nov 8 from 12:45-1:00pm ET at #ACAAI25! 👏 We explore how #HealthEducation impacts biologic adoption in children with moderate-to-severe pediatric #AtopicDermatitis. 🔗 bit.ly/4p45sB3

Thanks to partners @aafanational.bsky.social, #DBSA, & #NAPNAP 

We'll be sharing insights at #ACAAI25, the premier gathering for leaders in #allergy, #asthma, & #immunology. 👏

Thanks to partners like @aafanational.bsky.social & ACAAI. Together, we’re advancing evidence-based, accessible education for #clinicians, #patients, & #caregivers. 💜

🔗 bit.ly/47fU130

Come to this years American College of Allergy, Asthma & Immunology meeting - it is going to be great! I'll be there presenting the best from Annals from the last year. Hope to see you in Orlando! (register at annualmeeting.acaai.org/2025 )
@annalsacaai.bsky.social #ACAAI25